Literature DB >> 12110947

Mutations in the cardiac myosin-binding protein C gene are the predominant cause of familial hypertrophic cardiomyopathy in eastern Finland.

Pertti Jääskeläinen1, Johanna Kuusisto, Raija Miettinen, Päivi Kärkkäinen, Satu Kärkkäinen, Sami Heikkinen, Paula Peltola, Jussi Pihlajamäki, Ilkka Vauhkonen, Markku Laakso.   

Abstract

Hypertrophic cardiomyopathy (HCM) is a genetic disorder characterized by cardiac hypertrophy caused by mutations in genes encoding sarcomere proteins. This study screened all patients with HCM from the Kuopio University Hospital region in eastern Finland for variants in the cardiac myosin-binding protein C gene ( MYBPC3). All 35 exons of MYBPC3 were screened by the single-strand conformation polymorphism method in 37 unrelated patients with HCM. In MYBPC3 we identified seven novel (Gln1061X, IVS5-2A-->C, IVS14-13G-->A, Ex25DeltaLys, Pro147Leu, Ser236Gly, and Arg1138His) and two previously reported (Arg326Gln, Val896Met) variants, all of which are predicted to affect the structure of the encoded protein. Four of the nine variants, a nonsense mutation Gln1061X, a splice acceptor mutation (IVS5-2A-->C), a novel substitution in intron 14 (IVS14-13G-->A), and a novel 3-bp deletion in exon 25 (Ex25DeltaLys) were concluded to be disease-causing mutations because they cosegregated with the HCM phenotype or were absent in more than 200 normal chromosomes, or both. The mutation Gln1061X was found most frequently, being present in 6 families (23 subjects) while the other three mutations were found in single families each. Haplotype analysis indicated a likely founder effect among the families carrying the Gln1061X mutation. We found four novel mutations in MYBPC3, accounting for approx. 38% of familial and 24% of all cases of HCM. In our previous and unpublished studies no more frequent cause of HCM has been found in genetic analyses of other eight sarcomeric proteins. Consequently MYBPC3 is the predominant gene for HCM in eastern Finland. In addition, several amino acid substitutions in MYBPC3 suspected to be not associated with HCM were identified, indicating that some of the missense variants found in MYBPC3 are possibly not disease-causing mutations.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12110947     DOI: 10.1007/s00109-002-0323-9

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  21 in total

1.  A low prevalence of MYH7/MYBPC3 mutations among familial hypertrophic cardiomyopathy patients in India.

Authors:  Murali D Bashyam; Guroji Purushotham; Ajay K Chaudhary; Katika Madhumohan Rao; Vishal Acharya; Tabrez A Mohammad; Hampapathalu A Nagarajaram; Vuppaladadhiam Hariram; Calambur Narasimhan
Journal:  Mol Cell Biochem       Date:  2011-09-29       Impact factor: 3.396

2.  Short communication: the cardiac myosin binding protein C Arg502Trp mutation: a common cause of hypertrophic cardiomyopathy.

Authors:  Adam J Saltzman; Debora Mancini-DiNardo; Chumei Li; Wendy K Chung; Carolyn Y Ho; Stephanie Hurst; Julia Wynn; Melanie Care; Robert M Hamilton; Gregor W Seidman; Joshua Gorham; Barbara McDonough; Elizabeth Sparks; J G Seidman; Christine E Seidman; Heidi L Rehm
Journal:  Circ Res       Date:  2010-04-08       Impact factor: 17.367

3.  Two novel mutations of the MYBPC3 gene identified in Chinese families with hypertrophic cardiomyopathy.

Authors:  Jia Lin; Dong-Dong Zheng; Qin Tao; Jun-Hua Yang; Wen-Ping Jiang; Xiang-Jun Yang; Jian-Ping Song; Ting-Bo Jiang; Xun Li
Journal:  Can J Cardiol       Date:  2010-12       Impact factor: 5.223

4.  Fibrosis and wall thickness affect ventricular repolarization dynamics in hypertrophic cardiomyopathy.

Authors:  Mikko Jalanko; Heikki Väänänen; Mika Tarkiainen; Petri Sipola; Pertti Jääskeläinen; Kirsi Lauerma; Tiina Laitinen; Tomi Laitinen; Mika Laine; Tiina Heliö; Johanna Kuusisto; Matti Viitasalo
Journal:  Ann Noninvasive Electrocardiol       Date:  2018-07-04       Impact factor: 1.468

5.  Genotype-phenotype relationships involving hypertrophic cardiomyopathy-associated mutations in titin, muscle LIM protein, and telethonin.

Authors:  J Martijn Bos; Rainer N Poley; Melissa Ny; David J Tester; Xiaolei Xu; Matteo Vatta; Jeffrey A Towbin; Bernard J Gersh; Steve R Ommen; Michael J Ackerman
Journal:  Mol Genet Metab       Date:  2005-12-13       Impact factor: 4.797

Review 6.  Sarcomere gene mutations in hypertrophy and heart failure.

Authors:  Hiroyuki Morita; Ryozo Nagai; J G Seidman; Christine E Seidman
Journal:  J Cardiovasc Transl Res       Date:  2010-05-25       Impact factor: 4.132

7.  Large-scale mutation screening in patients with dilated or hypertrophic cardiomyopathy: a pilot study using DGGE.

Authors:  Raphael Zeller; Boris T Ivandic; Philipp Ehlermann; Oliver Mücke; Christian Zugck; Andrew Remppis; Evangelos Giannitsis; Hugo A Katus; Dieter Weichenhan
Journal:  J Mol Med (Berl)       Date:  2006-05-20       Impact factor: 4.599

8.  The role of sarcomere gene mutations in patients with idiopathic dilated cardiomyopathy.

Authors:  Daniel Vega Møller; Paal Skytt Andersen; Paula Hedley; Mads Kristian Ersbøll; Henning Bundgaard; Johanna Moolman-Smook; Michael Christiansen; Lars Køber
Journal:  Eur J Hum Genet       Date:  2009-03-18       Impact factor: 4.246

9.  Identification of pathogenic gene mutations in LMNA and MYBPC3 that alter RNA splicing.

Authors:  Kaoru Ito; Parth N Patel; Joshua M Gorham; Barbara McDonough; Steven R DePalma; Emily E Adler; Lien Lam; Calum A MacRae; Syed M Mohiuddin; Diane Fatkin; Christine E Seidman; J G Seidman
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-05       Impact factor: 11.205

10.  A human MYBPC3 mutation appearing about 10 centuries ago results in a hypertrophic cardiomyopathy with delayed onset, moderate evolution but with a risk of sudden death.

Authors:  Carolien H Teirlinck; Faïza Senni; Rajae El Malti; Danielle Majoor-Krakauer; Florence Fellmann; Gilles Millat; Xavier André-Fouët; François Pernot; Michaël Stumpf; Jean Boutarin; Patrice Bouvagnet
Journal:  BMC Med Genet       Date:  2012-11-10       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.